NCT07523282

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

A Study to Assess the Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).

Detailed description

The study consists of a screening period of up to 4 weeks, a treatment period, and a follow-up period of 1 year.

Conditions

• Autoimmune Disease
• Systemic Lupus Erythematosus
• Systemic Sclerosis (SSc)

Interventions

Type	Name	Description
DRUG	HN2302 Injection	Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.

Timeline

• Start date: 2026-04-28
• Primary completion: 2027-12-31
• Completion: 2028-06-30
• First posted: 2026-04-13
• Last updated: 2026-04-14

Locations

1 site across 1 country: China